PY
PYPD.US PolyPid
- Market cap
- USD 138M
- P/E
- -
- P/B
- 33.31x
- ROE
- -729.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PYPD.US undervalued?
Graham numberThe Graham number of PolyPid cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PolyPid fundamental analysis
No fundamental analysis for PolyPid yet.
PolyPid stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PolyPid
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPL…
Full company profilePolyPid financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
PolyPid annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -127K | -205K | -411K | -947K | -1.01M | -1.12M | -1.72M | -1.82M | -1.62M | - | - |
| Operating Income | -10.3M | -13.8M | -18.4M | -18.6M | -26.3M | -42.9M | -38.9M | -22.9M | -28.0M | -33.0M | -11.2M |
| EBITDA | -10.1M | -13.6M | -42.2M | -5.94M | -25.3M | -41.8M | -37.2M | -20.3M | -25.8M | -32.0M | -31.5M |
| Net Income | -11.4M | -54.5M | 5.92M | -6.91M | -35.3M | -40.7M | -39.5M | -23.9M | -29.0M | -34.2M | -28.4M |
| EPS | -19 | -93 | 6.68 | -7.79 | -28 | -33 | -31 | -17 | -4.91 | -2.09 | -1.20 |
| Balance Sheet | |||||||||||
| Total Assets | 19.2M | 23.0M | 14.5M | 33.8M | 75.8M | 44.2M | 26.0M | 15.4M | 25.2M | 22.3M | 40.1M |
| Total Liabilities | 53.2M | 112M | 96.2M | 2.83M | 3.07M | 8.28M | 20.1M | 17.5M | 17.5M | 11.3M | 36.2M |
| Shareholders' Equity | -34.0M | -88.6M | -81.7M | 30.9M | 72.8M | 36.0M | 5.83M | -2.10M | 7.68M | 11.0M | 3.90M |
| Cash & Short-term Investments | 17.8M | 17.9M | 7.33M | 26.6M | 44.5M | 32.2M | 12.6M | 5.61M | 15.6M | 12.9M | 15.7M |
| Total Debt | - | - | - | - | - | - | 13.7M | 11.8M | 9.62M | 2.80M | 1.26M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -9.73M | -12.3M | -16.7M | -17.4M | -21.6M | -32.4M | -34.3M | -17.2M | -22.0M | -27.9M | - |
| Capital Expenditure | 539K | 1.88M | 3.07M | 879K | 1.18M | 2.99M | 1.77M | 196K | 76.0K | 210K | 0.00 |
| Free Cash Flow | -10.3M | -14.2M | -19.8M | -18.2M | -22.8M | -35.4M | -36.1M | -17.4M | -22.0M | -28.1M | - |
| Ratios | |||||||||||
| ROE | - | - | - | -22.3% | -48.5% | -113.2% | -678.1% | - | -377.7% | -311.4% | -729.1% |
| ROA | -59.2% | -237.1% | 40.9% | -20.5% | -46.6% | -92.0% | -152.2% | -155.2% | -115.1% | -153.2% | -70.9% |
| Debt to Equity | - | - | - | - | - | - | 2.36x | - | 1.25x | 0.25x | 0.32x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
PolyPid dividends
PolyPid has not paid dividends in the last 9 fiscal years.
Last stock split: 1:30 on Sep 21, 2023.
Who owns PolyPid
- Insiders 12.34%
- Institutions 33.26%
- Public & others 54.40%
- Shares outstanding 21.1M
- Free float 12.4M
Top funds holding PYPD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| LUX IM Global Medtech HX | 9.90K | 0.05% | 0.00% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 3.01K | 0.01% | -81.36% | Aug 2026 |
Top institutions holding PYPD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| AIGH Capital Management, LLC | 1.50M | 7.12% | -5.58% | Jun 2026 |
| Rosalind Advisors, Inc. | 389K | 1.84% | -34.87% | Jun 2026 |
| Dafna Capital Management LLC | 208K | 0.98% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 132K | 0.62% | +13.02% | Sep 2026 |
| Morgan Stanley - Brokerage Accounts | 123K | 0.58% | -30.39% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 115K | 0.54% | 0.00% | Jun 2026 |
| ADAR1 Capital Management LLC | 104K | 0.49% | 0.00% | Jun 2026 |
| Symmetry Peak Management LLC | 101K | 0.48% | +15.70% | Jun 2026 |
| J. Goldman & Co LP | 99.2K | 0.47% | -33.66% | Jun 2026 |
| Jane Street Group LLC | 83.1K | 0.39% | +284.10% | Jun 2026 |
| Quadrature Capital Limited | 70.9K | 0.34% | 0.00% | Jun 2026 |
| Connective Capital Management LLC | 67.6K | 0.32% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 42.3K | 0.20% | -26.81% | Jun 2026 |
| Susquehanna International Group, LLP | 40.0K | 0.19% | 0.00% | Jun 2026 |
| Lumbard Investment Counseling LLC | 38.2K | 0.18% | 0.00% | Jun 2026 |
| HRT FINANCIAL LLC | 37.3K | 0.18% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 35.0K | 0.17% | +18.95% | Jun 2026 |
| Virtu Financial LLC | 18.9K | 0.09% | 0.00% | Jun 2026 |
| UBS Group AG | 18.5K | 0.09% | 0.00% | Jun 2026 |
| AXQ CAPITAL LP | 17.1K | 0.08% | 0.00% | Jun 2026 |
PolyPid company profile
- Company name
- PolyPid
- Ticker
- PYPD.US
- ISIN
- IL0011326795
- Exchange
- USA Stocks
- Listed since
- Jun 26, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 69
- Fiscal year end
- December
- Address
- 18 Hasivim Street, Petah Tikva, Israel, 4959376
- Phone
- 972 7 4719 5700
- Website
- polypid.com
About PolyPid
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
PolyPid management
9- Ms. Dikla Czaczkes AkselbradCEO & Director · born 1973
- Mr. Jonny MissulawinChief Financial Officer · born 1987
- Ms. Dalit HazanDeputy CEO and Executive VP of R&D, Clinical & Regulatory Affairs · born 1972
- Mr. Ori WarshavskyChief Operating Officer - US · born 1979
- Ms. Maria RubinExecutive Vice President of Operations
- Mr. Tal VilnaiGeneral Counsel & Corporate Secretary
- Ms. Rivi Lev-ariVice President of Human Resource
- Dr. Jean-Marc Hagai Pharm.D.Chief Commercial Officer
- Dr. Nurit Tweezer-Zaks M.B.A., M.D.Chief Medical Officer · born 1967